2. Search Result
Search Result
Results for "

TREK-2

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-104005
    ML335
    2 Publications Verification

    		 Potassium Channel Neurological Disease
    ML335 is a selective activator of both TREK-1 and TREK-2.
    ML335
  • HY-104027
    ML402
    1 Publications Verification

    		 Potassium Channel Neurological Disease
    ML402, a thiophene-carboxamide, is a selective K2P2.1(TREK-1) and K2P10.1(TREK-2) activator. ML402 is inactive against K2P4.1(TRAAK) .
    ML402
  • HY-108596
    BL-1249

    		Potassium Channel Inflammation/Immunology
    BL-1249 is a nonsteroidal anti-inflammatory agent (NSAID) and a potassium channel activator. BL-1249 potently activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2) with EC50 values of 5.5 μM and 8.0 μM, respectively. BL-1249 extracellular application activates all TREK subfamily members but has no effect on other K2P subfamilies. BL-1249 exhibits more selective for the bladder (EC50 of 1.26 μM) than vascular tissue (EC50 of 21.0 μM) [2].
    BL-1249
  • HY-W013712
    GI-530159

    		Potassium Channel Neurological Disease
    GI-530159 is a selective opener of TREK1 and TREK2 potassium channels. GI-530159 displays selectivity for TREK1/2 over TRAAK, TASK3 and other potassium channels, with an EC50 of 0.76 μM for TREK1. GI-530159 reduces rat dorsal root ganglion neuron excitability and shows potential analgesic effect .
    GI-530159
  • HY-172182
    ONO-2920632

    VU6011887

    		 Potassium Channel Neurological Disease
    ONO-2920632 is an orally active and central nervous system (CNS)-penetrant TREK activator, with EC50 values of 0.3 µM and 2.8 μM for TREK-1 and TREK-2, respectively. ONO-2920632 exhibits selectivity for other K2P channels (>91-fold selective versus TASK1, TASK2, TASK3, TRAAK, and TWIK2; 31-fold selective versus TRESK). ONO-2920632 possesses analgesic effects and can be used in research on pain, migraine, and neurological disorders.
    ONO-2920632
  • HY-179004
    ONO-9517601

    VU6022856

    		 Potassium Channel Neurological Disease
    ONO-9517601 is a potent, orally active, selective and CNS penetrant dual TREK-1/TREK-2 inhibitor (TREK-1 IC50= 0.067 μM, TREK-2 IC50= 0.23 μM). ONO-9517601 displays robust efficacy in an MK-801 (HY-15084B) challenge rat novel object recognition (NOR) paradigm. ONO-9517601 can be used for research on neurological and cognitive disorders .
    ONO-9517601
  • HY-179005
    ONO-7927846

    VU6024391

    		 Potassium Channel Neurological Disease
    ONO-7927846 is a potent, orally active, selective and CNS penetrant dual TREK-1/TREK-2 inhibitor (TREK-1 IC50= 0.11 μM, TREK-2 IC50= 0.29 μM). ONO-7927846 displays robust efficacy in an MK-801 (HY-15084B) challenge rat novel object recognition (NOR) paradigm. ONO-7927846 can be used for research on neurological and cognitive disorders .
    ONO-7927846
  • HY-116704
    11-Deoxyprostaglandin F2α

    		Potassium Channel Neurological Disease
    11-Deoxyprostaglandin F2α is an activator for TREK-2 channels with EC50 of 0.294 μM. 11-Deoxyprostaglandin F2α inhibits the K2P channel TREK-1 .
    11-Deoxyprostaglandin F2α
  • HY-160789
    C3001a

    		Potassium Channel Neurological Disease Inflammation/Immunology
    C3001a is a selective TREK-1 and TREK-2 channel activator with EC50 values of 12.81 μM and 11.31 μM, respectively. C3001a does not affect other two-pore domain K + (K2P) channels. C3001a binds to the cryptic binding site formed by P1 and TM4 in TREK-1. C3001a can be used for the study of pain and pancreatitis .
    C3001a
  • HY-RS07153
    KCNK10 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    KCNK10 Human Pre-designed siRNA Set A contains three designed siRNAs for KCNK10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    KCNK10 Human Pre-designed siRNA Set A
    KCNK10 Human Pre-designed siRNA Set A
  • HY-104005R
    ML335 (Standard)

    		Reference Standards Potassium Channel Neurological Disease
    ML335 (Standard) is the analytical standard of ML335 (HY-104005). This product is intended for research and analytical applications. ML335 is a selective activator of both TREK-1 and TREK-2.
    ML335 (Standard)
  • HY-108596R
    BL-1249 (Standard)

    		Reference Standards Potassium Channel Inflammation/Immunology
    BL-1249 (Standard) is the analytical standard of BL-1249 (HY-108596). This product is intended for research and analytical applications. BL-1249 is a nonsteroidal anti-inflammatory agent (NSAID) and a potassium channel activator. BL-1249 potently activates K2P2.1 (TREK-1) and K2P10.1 (TREK-2) with EC50 values of 5.5 μM and 8.0 μM, respectively. BL-1249 extracellular application activates all TREK subfamily members but has no effect on other K2P subfamilies. BL-1249 exhibits more selective for the bladder (EC50 of 1.26 μM) than vascular tissue (EC50 of 21.0 μM) [2].
    BL-1249 (Standard)
  • HY-104027R
    ML402 (Standard)

    		Reference Standards Potassium Channel Neurological Disease
    ML402 (Standard) is the analytical standard of ML402 (HY-104027). This product is intended for research and analytical applications. ML402, a thiophene-carboxamide, is a selective K2P2.1(TREK-1) and K2P10.1(TREK-2) activator. ML402 is inactive against K2P4.1(TRAAK) .
    ML402 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: